Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis.
Détails
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_1C0CC61D746E
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis.
Périodique
Vaccines
ISSN
2076-393X (Print)
ISSN-L
2076-393X
Statut éditorial
Publié
Date de publication
09/08/2021
Peer-reviewed
Oui
Volume
9
Numéro
8
Pages
883
Langue
anglais
Notes
Publication types: Case Reports
Publication Status: epublish
Publication Status: epublish
Résumé
Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a low-dose combination therapy of methotrexate and adalimumab, shortly before vaccine administration. Both near-normal and impaired immune responses to vaccines have been reported previously in patients treated with these drugs. Our case report shows that, even at low doses, combined methotrexate-adalimumab therapy can be associated with a weak immune response to the mRNA1273 vaccine in elderly patients.
Mots-clé
Pharmacology (medical), Infectious Diseases, Drug Discovery, Pharmacology, Immunology, SARS-CoV-2, adalimumab, antibody response, mRNA1273 vaccine, methotrexate
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/08/2021 6:32
Dernière modification de la notice
21/11/2022 9:16